Radioisotopes for Life // Ensuring European Supply – Stakeholders and Opportunities The European Nuclear Society organised the webinar “Radioisotopes for life. Ensuring European supply – Stakeholders and opportunities”, in collaboration with Euratom Supply Agency, SCK CEN (both ENS Members), PALLAS and the EU Commission DG ENER. Speakers, moderated by Kristoff Muylle (former President of the…
The World’s First Lutetium-177 Produced At Commercial Nuclear Reactor The Canadian nuclear operator Bruce Power announced the world’s first production of lutetium-177 (Lu-177) at a commercial nuclear reactor, its Bruce-7 nuclear power plant in Ontario. This milestone has been achieved thanks to the international cooperation between Bruce Power, Isogen (a Kinectrics and Framatome company), and…
Ensuring The Future – Outlook on Medical Radioisotopes and Uranium Supply Chains in Europe Interview with Euratom Supply Agency Director General Agnieszka Kazmierczak Medical radioisotopes are a crucial tool in beating cancer and other diseases, offering several and innovative solutions in terms of diagnostics and treatments. Despite this key role, the whole production and supply…
Framatome Announces New Investment Supporting Nuclear Medicine Framatome (ENS Corporate Member) announced that it acquired a minority stake in the French startup Global Morpho Pharma. With this investment, Framatome strengthens its activities serving nuclear medicine development and expands its support for the supply chain of Lutetium-177 and other promising isotopes for therapeutic applications. Global Morpho…
NRG And Curium Sign Contract For Production of Mo-99 NRG (ENS Corporate Member) and Curium have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m). Tc-99m is the most used isotope in nuclear medicine for diagnosing life-threatening diseases, such as cardiovascular diseases, lung and brain disorders and cancer. With…
Dutch Cabinet Supports Construction Of PALLAS Research Reactor The Dutch Minister of Health, Welfare and Sport Ernst Kuipers recently announced, that money has been set aside for the construction of the PALLAS reactor in Petten, North Holland, in the coming years. The ministry is reserving 30 million euros for the project this year and 129…
Medical Isotopes – International Experts Call For Action To Secure Supply International experts from irradiating reactors, other isotope producers, and direct users urgently call for a long-term strategy to prevent a critical shortage of research and production capacities. They jointly ask for a common framework that stimulates much needed policy changes and investments. The high-level…
Actinium-225, The Joint-Venture Pantera To Secure Its Production The Belgian Nuclear Research Centre SCK CEN (ENS Corporate Member) and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announced last week the name of their joint-venture: Pantera SA/NV, resulting from strategic R&D partnership between SCK CEN and IBA to enable the production…
Commercial Production Of Lutetium-177 Starts At Bruce NPP The international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM) announced today the start of commercial production of lutetium-177. It marks the first-of-its-kind achievement of a commercial power reactor with additional capability to commercially produce short-lived medical isotopes.…
High Flux Reactor In Petten Started Up In Advance The High Flux Reactor (HFR) in Petten, operated by NRG (ENS Corporate Member) started up a day early after maintenance to increase the availability of medical isotopes. The HFR has about 260 production days per year and has regular short maintenance shutdowns, and twice a year…